@article{5b133e723b134e9690010463fcdbf847,
title = "Effect of evolocumab on atherogenic lipoproteins during the peri- And early postinfarction period: A placebo-controlled, randomized trial",
keywords = "acute coronary syndrome, cholesterol, LDL, evolocumab, secondary prevention",
author = "Leucker, \{Thorsten M.\} and Blaha, \{Michael J.\} and Jones, \{Steven R.\} and Vavuranakis, \{Michael A.\} and Williams, \{Marlene S.\} and Hong Lai and Schindler, \{Thomas H.\} and Jacqueline Latina and Schulman, \{Steven P.\} and Gary Gerstenblith",
note = "Funding Information: Dr Leucker has received grants from American Heart Association Career Development Award, National Institutes of Health, and Amgen. Dr Blaha has received grants from the National Instititues of Health, FDA, AHA, Amgen, and Aetna; and is on the advisory board for Novo Nordisk, Bayer, Novartis, Amgen, Sanofi, Regeneron, and Akcea. Dr Vavuranakis has received grants from the National Institutes of Health. Dr Williams is on the scientific advisory board of Haemonet-ics; the Steering Committee for CME on DAPT–University of North Texas and Rockpointe; and is supported by an educational grant from Astra Zeneca. Dr Schindler has received grants from GE Healthcare Research study (F-Flurpirdaz Perfusion PET study - phase 3 clinical trial). Dr Gerstenblith has received grants from the National Institutes of Health. The other authors report no conflicts.",
year = "2020",
month = jul,
day = "28",
doi = "10.1161/CIRCULATIONAHA.120.046320",
language = "English",
volume = "142",
pages = "419--421",
journal = "Circulation",
issn = "0009-7322",
number = "4",
}